Reuters logo
BRIEF-Noxxon's NOX-A12 shown to synergize with checkpoint inhibitors in pre-clinical study
October 3, 2017 / 5:38 AM / 2 months ago

BRIEF-Noxxon's NOX-A12 shown to synergize with checkpoint inhibitors in pre-clinical study

Oct 3 (Reuters) - NOXXON PHARMA NV:

* NOXXON PUBLISHES PRECLINICAL PROOF-OF-CONCEPT DATA FOR LEAD COMPOUND NOX-A12 IN COMBINATION WITH CHECKPOINT INHIBITORS

* ‍NEW PRECLINICAL DATA DEMONSTRATE THAT INCREASING TUMOR-INFILTRATING T CELLS THROUGH INHIBITION OF CXCL12 BY NOX-A12 SYNERGIZES WITH PD-1 CHECKPOINT INHIBITION​

* ‍LEAD PROGRAM NOX-A12 WILL DELIVER TOP-LINE DATA FROM A KEYTRUDA COMBINATION TRIAL IN METASTATIC COLORECTAL AND PANCREATIC CANCER PATIENTS IN 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below